- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06088121
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia (ATC-P001)
Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The ATNC MDD-V1 system is a combined system of Transcranial Magnetic Stimulation and cognitive training and is a non-invasive therapeutic system for the improvement of Alzheimer patients' cognitive function.
A potential participant will undergo screening procedures to confirm eligibility to participate in the study, followed by randomization procedure to one of the study groups - treatment or sham (placebo) Patient will attend the clinic 5 times a week for 6 weeks, approximately an hour every day for treatment/sham. The patient will be required to return to the clinic for follow-up.
Up to 158 patients will be enrolled in up to 3 clinical sites in the Republic Korea.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shin Jinwoo
- Phone Number: +82314450566
- Email: jinwoo.shin@atnci.com
Study Contact Backup
- Name: Chun Woong Park
- Phone Number: +821050439405
- Email: chunwoong.park@atnci.com
Study Locations
-
-
Jung-gu
-
Daejeon, Jung-gu, Korea, Republic of, 35015
- Recruiting
- Chungnam National University Hospital
-
Contact:
- AT&C
- Phone Number: +82-31-445-0566
- Email: chunwoong.park@atnci.com
-
Principal Investigator:
- Ae Young MD LEE, PhD
-
-
Seo-gu
-
Busan, Seo-gu, Korea, Republic of, 49315
- Recruiting
- Dong-A University Hospital
-
Contact:
- AT&C
- Phone Number: +82-31-445-0566
- Email: chunwoong.park@atnci.com
-
Principal Investigator:
- Kyung Won MD Park, PhD
-
-
Seongbuk-gu
-
Seoul, Seongbuk-gu, Korea, Republic of, 02841
- Recruiting
- Korea University Anam Hospital
-
Contact:
- AT&C
- Phone Number: +82-31-445-0566
- Email: chunwoong.park@atnci.com
-
Principal Investigator:
- Kun Woo MD Park, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.
- Male or female age 60-85 years.
- Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.
- MMSE score 21 to 26.
- CDR 1 or GDS 3.
- Patients with a positive amyloid PET-CT.
- Patients who are judged physically capable of clinical trials based on medical records and examinations.
- Patient whose legal representative agrees to participate in a clinical trial and who can visit for the next observation with a guardian.
- Patients who agreed to participate in all 24-week clinical trials.
- Patients with normal ability to see and hear letters.
- Patients who speak Korean as their mother tongue
Exclusion Criteria:
- Patients with a central nervous system disease that can affect cognitive function and is likely to be another cause of cognitive decline, or a type of dementia other than Alzheimer's, is suspected.
- Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.
- History of Epileptic Seizures or Epilepsy.
- Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.
- Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.
- Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.
- Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.
- Cardiac pacemakers.
- Implanted medication pumps.
- Intracardiac lines.
- Patients who are currently taking medications that lower the convulsive seizure threshold.
- Significant heart disease.
- Significant renal disease, Significant hepatic disease.
- Contraindication for performing MRI scanning.
- Contraindication for performing amyloid PET-CT scanning.
- Patients who do not consent to TMS treatment and participation in this clinical trial.
- Patients who participated in other clinical trials 3 months before participating in this clinical trial.
- Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.
- Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.
Patients with a history of malignant tumors within the last 5 years.
- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).
- Patients who need to take medications suggested in concomitantly contraindicated drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ATNC MDD-V1
ATNC MDD-V1 treatment, synchronized TMS and cognitive training stimulation
|
Synchronized TMS and cognitive stimulation to 6 brain areas.
Other Names:
|
Sham Comparator: Sham TMS + Real Cog
The Control arm subjects will receive daily treatments five days a week for 6 consecutive weeks of Sham treatment of TMS and real cognitive training which is similar to the real treatment in visit frequency and procedure.
|
Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises.
Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer's Disease Assessment Scale-Cognition Score (Efficacy)
Time Frame: Week 24
|
Change from Baseline to 24 weeks in ADAS-Cog score.
ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer's Disease Assessment Scale-Cognitive(ADAS-cog) Score (Efficacy)
Time Frame: Week 7, 12
|
Change from Baseline to 7,12 weeks in ADAS-Cog score.
ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive
|
Week 7, 12
|
Korean-Mini Mental State Examination-2nd Edition(K-MMSE-2)(Efficacy)
Time Frame: Week 7, 12, 24
|
Change from Baseline to 7, 12 and 24 weeks in K-MMSE-2.
K-MMSE-2: Korean-Mini Mental State Examination-2nd Edition
|
Week 7, 12, 24
|
Clinical Dementia Rating(CDR)(Efficacy)
Time Frame: Week 7, 12, 24
|
Change from Baseline to 7, 12 and 24 weeks in CDR.
CDR: Clinical Dementia Rating
|
Week 7, 12, 24
|
Global Deterioration Scale(GDeps)(Efficacy)
Time Frame: Week 7, 12, 24
|
Change from Baseline to 7, 12 and 24 weeks in GDeps.
GDeps: Global Deterioration Scale
|
Week 7, 12, 24
|
Clinical Global Impression of Change(CGIC)(Efficacy)
Time Frame: Week 7, 12, 24
|
Change from Baseline to 7, 12 and 24 weeks in CGIC CGIC: Clinical Global Impression of Change
|
Week 7, 12, 24
|
Korean-Instrumental Activities of Daily Living(K-IADL)(Efficacy)
Time Frame: Week 7, 12, 24
|
Change from Baseline to 7, 12 and 24 weeks in K-IADL.
K-IADL: Korean-Instrumental Activities of Daily Living
|
Week 7, 12, 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events(AE's)(Safety)
Time Frame: Week 24
|
Adverse events (AE's), including serious adverse events (SAEs) occurring at any time during the trial and follow-up.
|
Week 24
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ae Young MD LEE, PhD, Chungnam National University Hospital
- Principal Investigator: Kun Woo MD Park, PhD, Korea University Anam Hospital
- Principal Investigator: Kyung Won MD Park, PhD, Dong-A University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CNUH 2023-03-027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Diseases
-
Brent MaselThe Moody FoundationCompletedChronic Traumatic Brain InjuryUnited States
-
Center for Vision Development, New Market, MarylandUnknownBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain Injury, Chronic | Injury, Brain, TraumaticUnited States
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...Enrolling by invitationMild Traumatic Brain Injury | Concussion, BrainUnited States
-
Oculogica, Inc.CompletedMild Traumatic Brain Injury | Concussion, BrainUnited States
-
Oculogica, Inc.Completed
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
University of AarhusAarhus University Hospital; Central Denmark RegionCompletedTraumatic Brain INjuryDenmark
-
Adel HelmyCambridge University Hospitals NHS Foundation TrustUnknownTraumatic Brain INjuryUnited Kingdom
Clinical Trials on ATNC MDD-V1 (Real TMS + Real Cog)
-
BeerYaakov Mental Health CenterUnknownPathological GamblingIsrael
-
University of Colorado, DenverNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...Completed
-
Medical University of South CarolinaCompletedGastric Bypass Surgery Pain ManagementUnited States
-
Northwestern UniversityRecruiting
-
Medical University of South CarolinaCompletedChronic PainUnited States
-
Northwestern UniversityCompletedHealthyUnited States
-
Medical University of South CarolinaCompleted
-
Michael J. Wesley, PhDNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Behavior Problem | NeurosciencesUnited States
-
Oregon Health and Science UniversityRecruitingTranscranial Magnetic Stimulation | Methamphetamine-dependence | Substance Use Disorders | Stimulant Dependence | Methamphetamine Abuse | Stimulant UseUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States